Schedule 13D ownership disclosure
Janux Therapeutics Inc
Security class unavailable · CUSIP: 47103J105
Event date: 2024-10-18
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 2,071,799
- Percent of class
- 4.0000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-24-110567
- Form type
- SC 13D
- Filer
- Avalon Ventures XI, L.P.
- CIK
- CIK 1652901
- Filed
- Oct 22, 2024
- Reporting period
- Oct 18, 2024
- Description
- Schedule 13D beneficial ownership